prevahex® CHX
The Ultimate Defense Against Deadly Superbugs

Revolutionizing the Final Step of Infection Prevention

Candida auris is a deadly superbug first identified in 2009,[1] and it has rapidly become an emerging global threat to patient health. It is often highly resistant to multiple major antifungal drug classes,[2] and the reported mortality rate for *C. auris* infections is between 30% and 60%.[3] Following several consecutive years of rapid annual increases in U.S. clinical prevalence (2018-2019: 44% increase, 2019-2020: 59% increase, 2020-2021: 95% increase),[4] *C. auris* is a grave and growing concern for patients, clinicians, and infection preventionists.

Prevahex$^{CHX®}$ and competitive dressings were tested for their ability to inhibit growth of *C. auris* in an *in vitro* zone of inhibition study. Dressing samples (10mm x 10mm) were placed directly into petri dishes of growth media which had been pre-inoculated with *C. auris* (ATCC# MYA-5001). Samples were incubated for 1 day before zone size was measured for each article. This study was conducted at an independent, contract laboratory under GLP and each dressing type was tested in quadruplicate.*

You've Done Everything Right, Now Protect the Site

New Prevahex$^{CHX®}$ antimicrobial dressings incorporate groundbreaking advanced technology utilizing **pure chlorhexidine,** providing rapid, broad-spectrum protection of wound and IV catheter sites.

Prevahex$^{CHX®}$ Antimicrobial Dressings:

- are the first & only dressings that utilize pure chlorhexidine (CHX) offering antimicrobial protection throughout the transparent areas of the dressing
- provide rapid onset of antimicrobial action against a broad spectrum of microorganisms, achieving a high level of efficacy (>5.0 $\log_{10}$ microbial reduction) within 24 hours, and maintaining that high level of efficacy for up to 7 days*
- are effective against gram-positive bacteria, gram-negative bacteria, and yeasts commonly found at wound and IV catheter sites
- demonstrate rapid bacterial elimination of multiple drug-resistant bacterial species both underneath and several millimeters beyond the perimeter of the dressing in *in vitro* laboratory studies*
- incorporate CHX directly into the transparent areas of the dressing which provides the dual benefit of both protecting the site and providing full site visualization
- are offered with integrated securement features to stabilize & secure IV catheters
- are available with a 3-year shelf-life in both single sterile format as well as bulk, non-sterile product format (for use in pre-packed, procedural kits)

entrotech life sciences

a member of the entro group of companies

Summary of Results from Comparative Dressing Test Against *Candida auris*:



- Prevahex CHX® demonstrated a zone of inhibition 50% wider than 3M® Tegaderm® Antimicrobial I.V. Advanced CHG
- Prevahex CHX® provided an area of protection 90% larger than 3M® Tegaderm® Antimicrobial I.V. Advanced CHG
- 3M® Tegaderm® and Covalon® SurgiClear® showed no efficacy

DRESSING TYPE	ANTIMICROBIAL TECHNOLOGY	ZONE OF INHIBITION BEYOND SAMPLE (mm)*	SURFACE AREA OF PROTECTION BEYOND SAMPLE (mm)*
Prevahex CHX® (1485CH)	CHX: 10% wt./wt.	18mm	528 mm^2
3M® Tegaderm® Antimicrobial I.V. Advanced CHG (9132)	CHG: 2% wt./wt.	12mm	278 mm^2
3M® Tegaderm® (1626W)	N/A	None	None
Covalon® SurgiClear® (TWBD1019)	CHA: 3% wt./wt. Silver Salts: 0.5% wt./wt.	None	None

*Note: *In vitro* effectiveness does not predict clinical performance. (Data on File: entrotech life sciences, llc, Columbus, OH)

References:
1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol Immunol*. 2009 Jan;53(1):41-4. **2.** Ostrowsky B, Greenko J, Adams E, Quinn M, O'Brien B, Chaturvedi V, Berkow E, Vallabhaneni S, Forsberg K, Chaturvedi S, Lutterloh E, Blog D; C. auris Investigation Work Group. Candida auris Isolates Resistant to Three Classes of Antifungal Medications - New York, 2019. *MMWR Morb Mortal Wkly Rep*. 2020 Jan 10;69(1):6-9. **3.** Chowdhary A, Jain K, Chauhan N. Candida auris Genetics and Emergence. *Annu Rev Microbiol*. 2023 Sep 15;77:583-602. **4.** Lyman M, Forsberg K, Sexton DJ, Chow NA, Lockhart SR, Jackson BR, Chiller T. Worsening Spread of Candida auris in the United States, 2019 to 2021. *Ann Intern Med*. 2023 Apr;176(4):489-495.

prevahex CHX®

To learn more about Prevahex CHX® antimicrobial dressings, please contact us at info@prevahexchx.com or visit prevahexchx.com

entrotech life sciences, llc
1245 Kinnear Rd.
Columbus, OH 43212
1 (415) 513-4494
www.entrotechlifesciences.com

MK-20272/Rev. A/022525